Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 174

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin

Open access
Schmalbrock, Laura K., Dolnik, Anna, Cocciardi, Sibylle, Sträng, Eric, Theis, Frauke, Jahn, Nikolaus, Panina, Ekaterina, Blätte, Tamara J., Herzig, Julia, Skambraks, Sabrina, Rücker, Frank G., Gaidzik, Verena I., Paschka, Peter, Fiedler, Walter, Salih, Helmut R., Wulf, Gerald, Schroeder, Thomas, Lübbert, Michael, Schlenk, Richard F., Thol, Felicitas, Heuser, Michael, Larson, Richard A., Ganser, Arnold, Stunnenberg, Hendrik G., Minucci, Saverio, Stone, Richard M., Bloomfield, Clara D., Döhner, Hartmut, Döhner, Konstanze, Bullinger, Lars · 2021 · Blood

Abstract

In the international randomized phase 3 RATIFY (Randomized AML Trial In FLT3 in patients less than 60 Years old) trial, the multikinase inhibitor midostaurin significantly improved overall and event-free survival in patients 18 to 59 years of age with FLT3-mutated acute myeloid leukemia (AML). However, only 59% of patients in the midostaurin arm achieved protocol-specified complete remission (CR), and almost half of patients achieving CR relapsed. To explore underlying mechanisms of resistance, we studied patterns of clonal evolution in patients with FLT3-internal tandem duplications (ITD)-positive AML who were entered in the RATIFY or German-Austrian Acute Myeloid Leukemia Study Group 16-10 trial and received treatment with midostaurin. To this end, paired samples from 54 patients obtained at time of diagnosis and at time of either relapsed or refractory disease were analyzed using conventional Genescan-based testing for FLT3-ITD and whole exome sequencing. At the time of disease resistance or progression, almost half of the patients (46%) became FLT3-ITD negative but acquired mutations in signaling pathways (eg, MAPK), thereby providing a new proliferative advantage. In cases with FLT3-ITD persistence, the selection of resistant ITD clones was found in 11% as potential drivers of disease. In 32% of cases, no FLT3-ITD mutational change was observed, suggesting either resistance mechanisms bypassing FLT3 inhibition or loss of midostaurin inhibitory activity because of inadequate drug levels. In summary, our study provides novel insights into the clonal evolution and resistance mechanisms of FLT3-ITD–mutated AML under treatment with midostaurin in combination with intensive chemotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.2020007626

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 174

Metadata

Authors
Schmalbrock, L. K., Dolnik, A., Cocciardi, S., Sträng, E., Theis, F., Jahn, N., Panina, E., Blätte, T. J., Herzig, J., Skambraks, S., Rücker, F. G., Gaidzik, V. I., Paschka, P., Fiedler, W., Salih, H. R., Wulf, G., Schroeder, T., Lübbert, M., Schlenk, R. F., Thol, F., Heuser, M., Larson, R. A., Ganser, A., Stunnenberg, H. G., Minucci, S., Stone, R. M., Bloomfield, C. D., Döhner, H., Döhner, K., & Bullinger, L.
Venue
Blood
Published
2021-06-03
Volume
137
Issue
22
Pages
3093-3104
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W3130105428
Cited by
174
References
8
FWCI
17.21
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. https://app.cochat.ai/papers/10.1182/blood.2020007626
The paper
Schmalbrock, L. K., Dolnik, A., Cocciardi, S., Sträng, E., Theis, F., Jahn, N., Panina, E., Blätte, T. J., Herzig, J., Skambraks, S., Rücker, F. G., Gaidzik, V. I., Paschka, P., Fiedler, W., Salih, H. R., Wulf, G., Schroeder, T., Lübbert, M., Schlenk, R. F., . . . Bullinger, L. (2021). Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. Blood. https://doi.org/10.1182/blood.2020007626

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.